Cerenome is trading 5.29% lower at $1.61, with no clear company-specific catalyst identified for the October 19, 2026 decline.
- The latest reported company releases were the October 6 product launch and October 8 Florida Blue agreement.
- The decline came amid positive broader market trading, which does not explain the move.
- An earlier analyst price-target change is not evidence of a new catalyst today.